Lupin gets USFDA nod for generic version of Prozac tablets to treat depressive disorder

The company has received approval for Fluoxetine Tablets from the US Food and Drug Administration(USFDA) to market its product which is a generic version of Eli Lilly and Company's Prozac tablets, Lupin said in a statement.

New Delhi: Drug maker Lupin Tuesday said it has received approval from the US health regulator to market Fluoxetine Tablets, used to treat a major depressive disorder, in the American market.

The company has received approval from the US Food and Drug Administration(USFDA) to market its product which is a generic version of Eli Lilly and Company's Prozac tablets, Lupin said in a statement.

Read Also: USFDA completes inspection of Nagpur facility with no observations: Lupin

The product is also indicated for the treatment of an obsessive-compulsive disorder, Bulimia Nervosa and panic disorder, it said.

Headquartered in Mumbai, Lupin's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis. The company was founded in 1968 by Desh Bandhu Gupta, who was a professor of chemistry at BITS-Pilani, Rajasthan.

Read Also: Lupin gets EIR from USFDA for Oral Dosage facility in Aurangabad